The US. FDA approved Kybella (Kythera) in April 2015 as a first-in-class treatment to approve the appearance of fat beneath the chin that causes what is sometimes referred to as “double chin”. The medication is administered into the fat under the chin.
This treatment option is unique as the chin area has not responded well to other non-invasive treatments.
In a May 2015 article published in ‘Practical Dermatology’, dermatologist Dr. Joel Schlessinger stated that submental fat (the fat beneath the chin) is a rapidly expanding area akin to eye lashes when Latisse came onto the market several years ago for eye lashes.
“What makes Kybella stand out even more is that it represents a whole new area, says Dr. Schlessinger. “It will dramatically revolutionize the treatment of chin fat and has potential to bring new patients to aesthetics practices and potentially re-activate old patients, as well.”
In addition clinical trial data indicates that those treated with Kybella reported an improvement in the amount of fat in the area under the chin. Moreover, when asked how happy, bothered, self-conscious, embarrassed, old and overweight they felt, they reported improvement on these feelings following treatment.
The procedure itself is performed in an outpatient setting and is relatively easy for patients with minimal if any downtime. Multiple treatments may be required depending on how much fat needs to be dissolved.
According to clinical trial data, the most common adverse reactions were associated with the injection site and included swelling, bruising, pain, numbness, rednessa and formation of small areas of firmness around the treatment area. A majority of these, however, were minor.